Researchers at UCSF have developed a method for generating bi- and multi-specific antibodies. Antibodies with bi- or multi-specificity hold great promise to lead the way in the next wave of biologic therapeutics. They are capable of recognizing multiple ligands simultaneously, thus can create synthetic specificity, and interact with multiple signaling pathways to maximize therapeutic benefits, offering advantages over traditional monoclonal antibodies. In the past however, their generation faces significant challenges such as heavy- and light-chain pairing. Incorrect dimerization produces impure biologics that increase complexity in production and purification. This invention solves the challenging light-chain pairing problem. Previous methods to solve this problem involve the addition of an undesired flexible linker, in vitro assembly or coupling mutations. These approaches suffer from poor production yields, low in vivo stability, and immunogenicity. They also face great difficulty in constructing multi-specific (beyond bispecific) antibodies with an Ig-like architecture. The researchers’ modular approach overcomes these issues to generate highly pure, bi- and multi-specific IgG’s with no additional mutations or excess amino acids. The method utilizes protease cleavable linkers to enforce correct light chain pairing and to allow for easy purifications; efficient removal of these linkers is performed post purification. The technology has been fully validated in a laboratory setting.
|European Patent Office||Published Application||2019-210|
|Patent Cooperation Treaty||Published Application||WO 2021/050527||03/18/2021||2019-210|
Additional Patent Pending
Bispecific Antibodies, Multispecific Antibodies, Platform Antibody Technology, Protease Cleavable Linkers, Light Chain Pairing, Antibody Generation